We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.
On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.
We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.
We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.
We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022.
SAN DIEGO, Aug. 22, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgA nephropathy, a rare kidney disorder and leading cause of end-stage kidney disease (ESKD). The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.
Wednesday, August 17, 2022 — We are thrilled to have been named as a finalist for the 2022 PM30 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year award. Trailblazer finalists are selected by a cross-section of experts from across the industry evaluating companies for innovation, talent development, and social responsibility. Read the full list of finalists.
Tuesday, August 9, 2022 — We are honored to be recognized by The Stevie Awards for Great Employers as a 2022 bronze award winner. The Stevies recognize some of the world’s best employers who help to create and foster great places to work. Stevie judges noted Travere’s purpose-driven culture, inspiring values, and commitment to employees’ well-being. Read the full list of 2022 winners.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update.
Retrophin is now Travere Therapeutics.
© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Jula Inrig Named to PharmaVoice 100 Top Industry Leaders List for 2022
NewsMonday, September 6, 2022 — today, our chief medical officer, Jula Inrig, M.D., was named to the PharmaVoice 100 Top Industry Leaders List for 2022. The PharmaVoice 100 awards recognize the most inspiring leaders in the life sciences, as decided by PharmaVoice readers. Jula’s inspiration? Being able to help as many people as possible, “I ask myself, what impact can I have on society today and for the future of health for patients?”